Solid Biosciences Inc.SLDBNASDAQ
LOADING
|||
R&D Expense Growth Accelerating
Trending higher, above historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
19.89%
↑ 203% above average
Average (36q)
6.56%
Historical baseline
Range
High:52.02%
Low:-39.58%
Volatility
1396.5%
High variability
| Period | Value |
|---|---|
| Q3 2025 | 19.89% |
| Q2 2025 | 4.86% |
| Q1 2025 | 0.47% |
| Q4 2024 | 12.60% |
| Q3 2024 | 40.42% |
| Q2 2024 | 3.12% |
| Q1 2024 | 22.13% |
| Q4 2023 | -7.48% |
| Q3 2023 | -15.55% |
| Q2 2023 | -19.71% |
| Q1 2023 | 15.69% |
| Q4 2022 | 52.02% |
| Q3 2022 | -39.58% |
| Q2 2022 | 16.22% |
| Q1 2022 | 36.66% |
| Q4 2021 | 1.18% |
| Q3 2021 | -7.01% |
| Q2 2021 | 9.20% |
| Q1 2021 | -9.65% |
| Q4 2020 | -2.01% |
| Q3 2020 | 19.31% |
| Q2 2020 | -31.61% |
| Q1 2020 | -27.34% |
| Q4 2019 | 18.75% |
| Q3 2019 | 5.47% |
| Q2 2019 | -7.13% |
| Q1 2019 | 31.00% |
| Q4 2018 | 20.99% |
| Q3 2018 | 7.99% |
| Q2 2018 | 13.96% |
| Q1 2018 | -0.14% |
| Q4 2017 | 12.50% |
| Q3 2017 | 23.38% |
| Q2 2017 | -1.44% |
| Q1 2017 | 23.56% |
| Q4 2016 | 0.00% |
| Q1 2016 | 0.00% |